TissueGene has completed enrolling patients in a US-based Phase II trial of its TG-C therapy, designed to treat patients with Grade 3 chronic degenerative joint disease (DJD) of the knee. Comprising human allogeneic chondrocytes, the TG-C ...
Tags: TG-C therapy, therapeutic protein, TG-C